(PharmaNewsWire.Com, November 15, 2017 ) Global Sterile Injectables Market: By Molecule Type (Large Molecules, Small Molecules), Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Immunoglobulins, Peptide Antibiotics, and Others), Disease Indication (Cancer, Diabetes, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Route of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Sterile Injectables market report gives a comprehensive outlook on sterile injectable across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on the sterile injectable market gives historical, current, and future market sizes (US$ Mn) of drug molecules, drug types, disease application, route of administration, end users, and geographic regions. This report studies sterile injectable market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the sterile injectable market report includes drug pipeline analysis, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analysed sterile injectable market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the sterile injectable market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of sterile injectables.
A sample of this report is available upon request @
The sterile injectable market estimated to be valued US$ 361 Bn in 2016 and poised to grow at CAGR 7.3%. The market for sterile injectable projected to reach US$ 552 Bn by 2023.
Do the burgeoning product pipelines and drug patent expiries have a positive impact on the market?
The rising shift of pharmaceutical and biotechnology firms towards the development of medications for chronic diseases such as cancer, diabetes, and cardiovascular and among others have created ample growth opportunities for players in the market. Moreover, biologic have become a larger part of product pipelines of several drug developers, which could affect market growth positively over the forecast period. For instance, there are around 2,500 injectable products are in the developmental stage. Moreover, rising product patent expiries of several blockbusters in recent times expected to propel market growth over the forecast period. For instance, in 2015, Teva Pharmaceutical Industries Ltd. lost the patent for its top-selling multiple sclerosis drug Copaxone.
To view TOC of this report is available upon request @
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
